Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
06 févr. 2025 07h00 HE
|
Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
04 févr. 2025 11h47 HE
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If...
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
28 janv. 2025 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals,...
America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
23 janv. 2025 12h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
22 janv. 2025 11h32 HE
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options ...
INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline
21 janv. 2025 08h33 HE
|
Berger Montague
PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (NASDAQ: REGN). The lawsuit...
NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline
17 janv. 2025 08h33 HE
|
Berger Montague
PHILADELPHIA, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the...
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
13 janv. 2025 06h30 HE
|
Regeneron Pharmaceuticals, Inc.
Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
13 janv. 2025 06h05 HE
|
Regeneron Pharmaceuticals, Inc.
The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers)...
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
10 janv. 2025 17h55 HE
|
DiCello Levitt LLP
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:...